Roth Capital Issues Pessimistic Outlook for MNMD Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Research analysts at Roth Capital decreased their Q3 2025 earnings estimates for Mind Medicine (MindMed) in a research report issued on Monday, August 4th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of ($0.49) per share for the quarter, down from their prior forecast of ($0.39). The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share. Roth Capital also issued estimates for Mind Medicine (MindMed)’s Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($2.13) EPS, FY2027 earnings at $0.84 EPS, FY2028 earnings at $4.21 EPS and FY2029 earnings at $7.77 EPS.

Mind Medicine (MindMed) (NASDAQ:MNMD) last announced its quarterly earnings data on Thursday, July 31st. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.12).

MNMD has been the subject of several other research reports. Cantor Fitzgerald raised Mind Medicine (MindMed) to a “strong-buy” rating in a report on Tuesday, May 13th. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Mind Medicine (MindMed) in a report on Friday, August 1st. Finally, Oppenheimer initiated coverage on shares of Mind Medicine (MindMed) in a research note on Monday. They set an “outperform” rating and a $25.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $24.71.

Mind Medicine (MindMed) Stock Up 2.6%

NASDAQ:MNMD opened at $9.89 on Wednesday. The firm has a market capitalization of $747.19 million, a P/E ratio of -6.46 and a beta of 2.49. The company’s fifty day moving average price is $7.97 and its 200-day moving average price is $7.17. Mind Medicine has a 1-year low of $4.70 and a 1-year high of $10.44. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.98 and a quick ratio of 4.98.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. CWM LLC grew its position in shares of Mind Medicine (MindMed) by 67.4% in the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Diadema Partners LP purchased a new stake in Mind Medicine (MindMed) in the 4th quarter valued at $33,000. Black Swift Group LLC acquired a new stake in shares of Mind Medicine (MindMed) in the 1st quarter worth $63,000. CreativeOne Wealth LLC purchased a new position in shares of Mind Medicine (MindMed) during the 1st quarter worth $67,000. Finally, Virtus ETF Advisers LLC acquired a new position in Mind Medicine (MindMed) in the 4th quarter valued at about $70,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Insider Activity at Mind Medicine (MindMed)

In other Mind Medicine (MindMed) news, CEO Robert Barrow sold 26,491 shares of the business’s stock in a transaction that occurred on Wednesday, June 25th. The stock was sold at an average price of $6.80, for a total transaction of $180,138.80. Following the completion of the sale, the chief executive officer directly owned 830,065 shares in the company, valued at approximately $5,644,442. The trade was a 3.09% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Sullivan sold 11,491 shares of the firm’s stock in a transaction that occurred on Wednesday, June 25th. The shares were sold at an average price of $6.80, for a total value of $78,138.80. Following the completion of the transaction, the insider owned 305,130 shares in the company, valued at approximately $2,074,884. This trade represents a 3.63% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 45,830 shares of company stock valued at $311,644. 2.45% of the stock is owned by company insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.